title: Tenofovir alafenamide: safer, but questions remain.
authors.affiliation: The Kirby Institute for Infection and Immunity in Society, UNSW Australia, Sydney, NSW 2052, Australia. Electronic address: mboyd@kirby.unsw.edu.au.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Boyd
authors.affiliation: The Kirby Institute for Infection and Immunity in Society, UNSW Australia, Sydney, NSW 2052, Australia.
authors.forename: David A
authors.initials: DA
authors.lastname: Cooper
mesh_terms: D000225:Adenine / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy; D015497:HIV-1; D006801:Humans; D063065:Organophosphonates / Q000627:therapeutic use; D000068698:Tenofovir
chemical_list: D019380:Anti-HIV Agents; D000998:Antiviral Agents; D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine